Most comprehensive coverage of the P450 drug metabolising genes offered to date in this new bioarray, designed for screening clinical trial populations
Amersham Biosciences has announced the addition of the new CodeLink Human P450 SNP Bioarray to its existing CodeLink expression and SNP bioarray range.
The CodeLink Human P450 SNP Bioarray genotypes 110 single nucleotide polymorphisms (SNPs) within nine P450 genes (CYP1A1, 1A2, 1B1, 2C9, 2C19, 2D6, 2E, 3A4, and 3A5) offering comprehensive coverage of the P450 drug metabolism genes for research applications in genotyping and pharmacogenomic profiling.
The CodeLink Human P450 SNP Bioarray is designed for screening clinical trial populations to determine their toxicogenetic profiles and for the discovery of novel associations between P450 genotypes and phenotypes.
To maximise throughput, the bioarray contains a set of four identical arrays of 110 SNPs to enable the testing of four individual samples simultaneously.
Customers benefit from the speed and flexibility of the system and the ability to individually score each sample with high accuracy.
"The new CodeLink Human P450 SNP Bioarray will aid the discovery of clinically significant genetic markers in populations studies for researchers involved in high throughput toxicogenomic screening,'" said Sam Raha, vice president CodeLink at Amersham Biosciences.
"An extension to our existing CodeLink line, the design of this new bioarray maximizes throughput and minimises labor and cost with the ability to process four different samples on each bioarray simultaneously."
